News coverage about Athenex (NASDAQ:ATNX) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Athenex earned a media sentiment score of 0.05 on Accern’s scale. Accern also gave news headlines about the company an impact score of 45.1870577931096 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Athenex (NASDAQ:ATNX) opened at $15.87 on Tuesday. Athenex has a one year low of $11.21 and a one year high of $20.79.
Athenex (NASDAQ:ATNX) last posted its quarterly earnings data on Thursday, November 9th. The company reported ($0.30) EPS for the quarter. equities analysts predict that Athenex will post -2.75 EPS for the current year.
Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.